Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants

计划入组 45 人 · 首次发布于 2006 年 3 月 29 日

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

计划入组 100 人 · 首次发布于 2024 年 10 月 30 日

Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants

计划入组 45 人 · 首次发布于 2010 年 6 月 8 日

PIV5-MERS-S

Parainfluenza Virus(Meissa Vaccines)

Parainfluenza virus vaccine (MedImmune LLC)

Assembly Biosciences

United States

AbbVie CDR (CAD Hedged)

United States

Enanta Pharmaceuticals

United States

Vicebio Secures $100 Million to Advance RSV and hMPV Combination Vaccine

RSV Vaccine Development Surges with New Approvals and Diverse Strategies

Blue Lake and CyanVac Report Promising Phase 1 Results for Intranasal COVID-19 Vaccine CVXGA